| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Research Institute of the Hospital for Joint Diseases and Medical Center, Mount Sinai School of Medicine, New York, New York 10035
MTW9-D, a rat mammary tumor derived from MTW9 by chronic administration of the dopamine antagonist drug R33,812 shows ovariectomy-induced regression (OIR). MTW9-MtT is also a variant of MTW9, grown by coimplantation of a mammosomatotropic tumor MtTW10, but it does not show OIR. However, when the mammosomatotropic tumor (MtT) is resected, the tumor regresses and shows rapid OIR; implantation of MtT into animals bearing MTW9-D prevents OIR following drug withdrawal. The estradiol receptor (ER) from MTW9-D cytosol binds to DNA-cellulose significantly more than that from MTW9-MtT. After MtT resection, the mammary tumor ER binds to DNA-cellulose, as well as ER from MTW9-D, whereas implantation of MtT into animals bearing MTW9-D decreases ER binding to DNA-cellulose. The significance of these findings in relation to possible clinical application is discussed.
1 This investigation was supported by Grants P 30 14194 and CA 10064 awarded by the National Cancer Institute, Department of Health, Education, and Welfare, and American Cancer Society Grant BC-312 awarded by the American Cancer Society, Inc., New York, N. Y.
2 To whom requests for reprints should be addressed.
Received 5/25/79. Accepted 12/20/79.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |